The effect of the probiotic bacteria Akkermansia Muciniphila in intestinal homeostasis and dss-induced inflammation in mice
- Authors: Sheynova A.D.1,2, Podosokorskaya O.A.3, Gubernatorova E.O.3
-
Affiliations:
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
- Lomonosov Moscow State University
- Winogradsky Institute of Microbiology, Research Centre of Biotechnology of the Russian Academy of Sciences
- Issue: Vol 14, No 3 (2024)
- Pages: 564-568
- Section: SHORT COMMUNICATIONS
- URL: https://bakhtiniada.ru/2220-7619/article/view/262081
- DOI: https://doi.org/10.15789/2220-7619-TEO-16882
- ID: 262081
Cite item
Full Text
Abstract
Akkermansia muciniphila is a Gram-negative anaerobic bacterium, a component of the normal human intestinal microbiota. A decrease in the presence of this bacterium is associated with pathologies, including metabolic disorders, intestinal inflammation and colorectal cancer. A. muciniphila is a probiotic approved for patients with diabetes and obesity. In recent years, A. muciniphila was studied in the control of intestinal inflammation and colorectal cancer. The exact mechanisms of A. muciniphila action remain unclear, while the use of different administration protocols shows different effects in mouse models of colitis and colorectal cancer. We reported that A. muciniphila has distinct effects on intestinal mucin production depending on viable or pasteurized form of bacteria. Another factor affecting the outcome of the A. muciniphila administration is the number of bacteria. To address how the dose of bacteria may affect the severity of acute intestinal inflammation wild-type mice were subjected to daily oral injections with 10⁸ CFU or 109 CFU of viable A. muciniphila for two weeks; the control group was injected with PBS. After that, groups were subjected to the induction of acute colitis by adding 7% DSS to drinking water for five days. 8 days after the onset of colitis induction, a morphometric assessment of the colitis severity was performed. Mice given a high dose of A. muciniphila (109 CFU) were found to be protected from developing severe colitis. RT-PCR analysis of colon samples from mice receiving a high dose of bacteria showed an increase in the gene expression of antimicrobial peptides, IL-17A, IL-17F. Interestingly, the protective effect of A. muciniphila was observed only in a high dose group, but not in a low dose group. Our data suggest that A. muciniphila provides the protective effect in colitis and highlight the importance of selecting the dose of the bacterium for proper interpretation.
Full Text
##article.viewOnOriginalSite##About the authors
Anna D. Sheynova
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences; Lomonosov Moscow State University
Author for correspondence.
Email: isinfo@eimb.ru
Senior Laboratory Assistant, Laboratory of Molecular Mechanisms of Immunity, Master's Student of the Department of Immunology
Russian Federation, 119991, Moscow, Vavilova str., 32; MoscowO. A. Podosokorskaya
Winogradsky Institute of Microbiology, Research Centre of Biotechnology of the Russian Academy of Sciences
Email: isinfo@eimb.ru
PhD (Biology), Senior Researcher, Extremophiles Metabolism Laboratory, Winogradsky Institute of Microbiology
Russian Federation, MoscowE. O. Gubernatorova
Winogradsky Institute of Microbiology, Research Centre of Biotechnology of the Russian Academy of Sciences
Email: isinfo@eimb.ru
PhD (Biology), Senior Researcher, Extremophiles Metabolism Laboratory, Winogradsky Institute of Microbiology
Russian Federation, MoscowReferences
- Chen T., Wang R., Duan Z., Yuan X., Ding Y., Feng Z., Bu F., Liu L., Wang Q., Zhou J., Zhu L., Ni Q., Shi G., Chen Y. Akkermansia muciniphila Protects Against Psychological Disorder-Induced Gut Microbiota-Mediated Colonic Mucosal Barrier Damage and Aggravation of Colitis. Front. Cell. Infect. Microbiol., 2021, vol. 11: 723856. doi: 10.3389/fcimb.2021.723856]
- Gubernatorova E.O., Gorshkova E.A., Bondareva M.A., Podosokorskaya O.A., Sheynova A.D., Yakovleva A.S., Bonch-Osmolov skaya E.A., Nedospasov S.A., Kruglov A.A., Drutskaya M.S. Akkermansia muciniphila — friend or foe in colorectal cancer? Front. Immunol., 2023, vol. 14: 1303795. doi: 10.3389/fimmu.2023.1303795]
- Kang C.S., Ban M., Choi E.J., Moon H.G., Jeon J.S., Kim D.K., Park S.K., Jeon S.G., Roh T.Y., Myung S.J., Gho Y.S., Kim J.G., Kim Y.K. Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PLoS One, 2013, vol. 8, no. 10: e76520. doi: 10.1371/journal.pone.0076520
- Kruglov A.A., Grivennikov S.I., Kuprash D.V., Winsauer C., Prepens S., Seleznik G.M., Eberl G., Littman D.R., Heikenwalder M., Tumanov A.V., Nedospasov S.A. Nonredundant function of soluble LTalpha3 produced by innate lymphoid cells in intestinal homeostasis. Science, 2013, vol. 342, no. 6163, pp. 1243–1246. doi: 10.1126/science.1243364
- Qu S., Fan L., Qi Y., Xu C., Hu Y., Chen S., Liu W., Liu W., Si J. Akkermansia muciniphila Alleviates Dextran Sulfate Sodium (DSS)-Induced Acute Colitis by NLRP3 Activation. Microbiol. Spectr., 2021, vol. 9, no. 2: e0073021. doi: 10.1128/Spectrum.00730-21
- Rodrigues V.F., Elias-Oliveira J., Pereira I.S., Pereira J.A., Barbosa S.C., Machado M.S. G., Carlos D. Akkermansia muciniphila and Gut Immune System: A Good Friendship That Attenuates Inflammatory Bowel Disease, Obesity, and Diabetes. Front. Immunol., 2022, vol. 13: 934695. doi: 10.3389/fimmu.2022.934695
- Wang X., Lin S., Wang L., Cao Z., Zhang M., Zhang Y., Liu R., Liu J. Versatility of bacterial outer membrane vesicles in regulating intestinal homeostasis. Sci. Adv., 2023, vol. 9, no. 11: eade5079 doi: 10.1126/sciadv.ade5079
- Wu H.J., Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes, 2012, vol. 3, no. 1, pp. 4–14. doi: 10.4161/gmic.19320
- Zhai R., Xue X., Zhang L., Yang X., Zhao L., Zhang C. Strain-Specific Anti-inflammatory Properties of Two Akkermansia muciniphila Strains on Chronic Colitis in Mice. Front. Cell. Infect. Microbiol., 2019, vol. 9: 239. doi: 10.3389/fcimb.2019.00239
Supplementary files
